To prevent immune pathology, the immune system employs several inhibitory mechanisms, among which inhibitory immune receptors. These receptors provide an activation threshold and thereby regulate or terminate immune cell activation, hence contributing to immune homeostasis. We question how inhibitory receptors prevent collateral damage and unwanted inflammatory responses and whether these receptors can be used as therapeutic targets to dampen immune responses where needed.
We do basic work identifying novel molecular interactions, function and signaling pathways of these receptors and we translate this to human disease. Our work currently centers around four inhibitory receptors (LAIR-1, SIRL-1, Allergin-1 and CD200R). We are particularly interested in neutrophils, which can cause severe collateral damage to tissues. Main focus are respiratory diseases such as respiratory syncytial virus (RSV) infection and auto-immune conditions, such as systemic lupus erythematosus. We closely collaborate with clinicians which allows us to study the relevance of inhibitory receptors to these diseases using primary patient samples.
Ever since the success of cancer immune therapy through inhibitory receptors, this field and thus possibilities are rapidly expanding. Our basic and translational research is geared towards the potential use of inhibitory receptor agonists to specifically dampen unwanted inflammation and immune pathology in patients.
- Van Avondt K, van Sorge N, Meyaard L. Bacterial immune evasion through manipulation of host inhibitory immune signaling. PLoS Pathog. 2015 11(3): e1004644. View publication
- van Avondt K, Fritsch-Stork F, Derksen RH, Meyaard L. SIRL-1 suppresses the release of neutrophil extracellular traps in systemic lupus erythematosus. PLoS ONE 2013 8(10): e78459. View publication
- Karnam G, Rygiel TP, Raaben M, Grinwis GC, Coenjaerts FE, Ressing ME, Rottier PJ, de Haan CA, Meyaard L. CD200 receptor controls sex-specific TLR7 responses to viral infection. PLoS Pathog. 2012 8:e1002710. View publication
- Olde Nordkamp MJ, van Roon JA, Douwes M, de Ruiter T, Urbanus RT, Meyaard L. Enhanced secretion of Leukocyte-Associated Immunoglobulin-like Receptor (LAIR)-2 and soluble LAIR-1 in rheumatoid arthritis: LAIR-2 is a more efficient antagonist of the LAIR-1-collagen inhibitory interaction than soluble LAIR -1. Arthritis Rheum. 2011. 63:3749-3757. View publication
- Lebbink RJ, de Ruiter T, Adelmeijer J, Brenkman AB, van Helvoort JM, Koch M, Farndale RW, Lisman T, Sonnenberg A, Lenting PJ, Meyaard L. Collagens are functional, high-affinity ligands for the inhibitory immune receptor LAIR-1. J Exp Med. 2006.203:1419-1425. View publication
Members group Meyaard
- Louis Bont, MD PhD (Professor of pediatric respiratory infections)